Prognostic Significance of the Centers for Disease Cont
High-Sensitivity C-Reactive Protein Cut Points for Card
Patients With Stable Coronary Artery Disease

Circulation

115, 1528-1536

DOI: 10.1161/circulationaha.106.649939

Citation Report

#	Article	IF	Citations
1	Risk Stratification for Heart Failure and Death in an Acute Coronary Syndrome Population Using Inflammatory Cytokines and N-Terminal Pro-Brain Natriuretic Peptide. Clinical Chemistry, 2007, 53, 2112-2118.	1.5	55
2	Variants in the CRP Gene as a Measure of Lifelong Differences in Average C-Reactive Protein Levels: The Cardiovascular Risk in Young Finns Study, 1980 2001. American Journal of Epidemiology, 2007, 166, 760-764.	1.6	32
3	Challenges in developing DNA and RNA biomarkers of inflammation. Biomarkers in Medicine, 2007, 1, 293-312.	0.6	20
4	Clinical significance of high-sensitivity C-reactive protein in cardiovascular disease. Biomarkers in Medicine, 2007, 1, 229-241.	0.6	14
5	C-Reactive Protein Cutoff-Point of 0.65 mg/L may be Appropriate not Only as a Component of Metabolic Syndrome but Also as a Risk Predictor of Cardiovascular Disease. Circulation Journal, 2007, 71, 1501.	0.7	9
6	We are on the Way to Finding the Cutoff Point for High-Sensitivity C-Reactive Protein in Japanese. Circulation Journal, 2007, 71, 1502.	0.7	1
7	C-Reactive Protein Cutoff Point as a Risk Factor for Coronary Spasm. Circulation Journal, 2007, 71, 1832.	0.7	2
8	Evaluating the role of biomarkers for cardiovascular risk prediction: focus on CRP, BNP and urinary microalbumin. Expert Review of Molecular Diagnostics, 2007, 7, 793-804.	1.5	25
9	Anithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy. Thrombosis Journal, 2007, 5, 11.	0.9	2
10	Biomarkers of atherosclerosis: Clinical applications. Current Cardiology Reports, 2008, 10, 497-504.	1.3	34
11	The elusive link between high sensitivity C-reactive protein and carotid subclinical atherosclerosis in coronary artery bypass grafting candidates: A cross-sectional study. Cardiovascular Ultrasound, 2008, 6, 23.	0.5	5
12	Câ€reactive protein specifically binds to FcÎ³ receptor typeâ€„I on a macrophageâ€like cell line. European Journal of Immunology, 2008, 38, 1414-1422.	1.6	31
13	Interleukin-1Î² stimulates acute phase response and C-reactive protein synthesis by inducing an NFÎºB- and C/EBPÎ²-dependent autocrine interleukin-6 loop. Molecular Immunology, 2008, 45, 2678-2689.	1.0	76
15	Predictive value of elevated neutrophilâ€“lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease. Clinica Chimica Acta, 2008, 395, 27-31.	0.5	306
16	Are acute phase protein levels the link between atrial arrhythmias and inflammation?. Heart Rhythm, 2008, 5, 222-223.	0.3	0
17	Association between plasma thiols and immune activation marker neopterin in stable coronary heart disease. Clinical Chemistry and Laboratory Medicine, 2008, 46, 648-54.	1.4	7
18	Adipose Macrophage Infiltration Is Associated With Insulin Resistance and Vascular Endothelial Dysfunction in Obese Subjects. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1654-1659.	1.1	329
19	The use of high-sensitivity assays for C-reactive protein in clinical practice. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 621-635.	3.3	123

#	Article	IF	Citations
20	Human C-Reactive Protein Activates Monocyte-Derived Dendritic Cells and Induces Dendritic Cell-Mediated T-Cell Activation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 511-518.	1.1	50
21	The Metabolic Syndrome as a Concept of Adipose Tissue Disease. Hypertension Research, 2008, 31, 1283-1291.	1.5	93
22	Câ€reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study. European Journal of Heart Failure, 2008, 10, 63-69.	2.9	62
23	C-reactive protein and memory function suggest antagonistic pleiotropy in very old nondemented subjects. Age and Ageing, 2008, 38, 237-241.	0.7	28
24	Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial. Yearbook of Medicine, 2008, 2008, 367-369.	0.1	0
25	Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease. Yearbook of Cardiology, 2008, 2008, 231-233.	0.0	0
26	Natriuretic Peptides and Inflammatory Markers for Risk Stratification in Patients with Ischemic Heart Disease. , 0, , 53-74.		1
27	Screening, Prevention and Treatment. Canadian Pharmacists Journal, 2008, 141, S23-S23.	0.4	0
28	Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease. Yearbook of Medicine, 2008, 2008, 369-371.	0.1	0
29	FADS genotypes and desaturase activity estimated by the ratio of arachidonic acid to linoleic acid are associated with inflammation and coronary artery disease. American Journal of Clinical Nutrition, 2008, 88, 941-949.	2.2	286
30	C-Reactive Protein and Atherosclerosis: An Update. Vascular Disease Prevention, 2008, 5, 178-182.	0.2	0
31	Retrospective analysis of risk factors in young patients with coronary artery disease in Guangdong and Zhejiang, China. Acta Cardiologica, 2009, 64, 195-199.	0.3	4
32	Inflammation: A Link Between Hypertension and Atherosclerosis. Current Hypertension Reviews, 2009, 5, 40-48.	0.5	25
33	Different Apparent Prognostic Value of hsCRP in Type 2 Diabetic and Nondiabetic Patients with Acute Coronary Syndromes. Clinical Chemistry, 2009, 55, 365-368.	1.5	25
34	Concentrations of C-Reactive Protein and B-Type Natriuretic Peptide 30 Days after Acute Coronary Syndromes Independently Predict Hospitalization for Heart Failure and Cardiovascular Death: Just Another Brick in the Wall?. Clinical Chemistry, 2009, 55, 203-205.	1.5	2
35	High-Calorie-Expenditure Exercise. Circulation, 2009, 119, 2671-2678.	1.6	171
36	Evaluation of the VITROS 5,1 FS analyzer in a large clinical laboratory: comparison of methods using different specimens and chemistry systems / Evaluation des Systems VITROS 5,1 FS in einem groÃŸen klinischen Laboratorium: Methodenvergleiche mit verschiedenen Probenmaterialien und Systemen. Laboratoriums Medizin, 2009, 33, 22-32.	0.1	1
37	Concentrations of C-Reactive Protein and B-Type Natriuretic Peptide 30 Days after Acute Coronary Syndromes Independently Predict Hospitalization for Heart Failure and Cardiovascular Death. Clinical Chemistry, 2009, 55, 265-273.	1.5	54

#	Article	IF	Citations
38	Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials. Heart, 2009, 95, 107-112.	1.2	26
39	Plasma CRP Levels in Premenopausal Women with Major Depression: A 12-Month Controlled Study. Hormone and Metabolic Research, 2009, 41, 641-648.	0.7	25
40	High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. European Heart Journal, 2009, 30, 1066-1072.	1.0	148
41	Inflammatory Markers and Outcomes in Cardiovascular Disease. PLoS Medicine, 2009, 6, e1000147.	3.9	8
42	Growth-Differentiation Factor-15 for Risk Stratification in Patients With Stable and Unstable Coronary Heart Disease. Circulation: Cardiovascular Genetics, 2009, 2, 286-292.	5.1	113
43	How to Identify the Asymptomatic High-Risk Patient?. Current Problems in Cardiology, 2009, 34, 539-577.	1.1	3
44	Usefulness of Elevations in Serum Choline and Free F2-Isoprostane to Predict 30-Day Cardiovascular Outcomes in Patients With Acute Coronary Syndrome. American Journal of Cardiology, 2009, 104, 638-643.	0.7	58
45	Vitamin C treatment reduces elevated C-reactive protein. Free Radical Biology and Medicine, 2009, 46, 70-77.	1.3	92
46	Abnormal function of highâ€density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis and Rheumatism, 2009, 60, 2870-2879.	6.7	120
47	Myocardial inflammation and non-ischaemic heart failure: is there a role for C-reactive protein?. Basic Research in Cardiology, 2009, 104, 591-599.	2.5	38
48	Predictor of underlying myocardial damage in normally functioning left ventricle with narrow QRS complex: relationship between QRS duration at right ventricle pacing and iodine-123 metaiodobenzylguanidine myocardial scintigraphy. Annals of Nuclear Medicine, 2009, 23, 639-641.	1.2	1
49	Biomarkers of atherosclerosis: Clinical applications. Current Cardiovascular Risk Reports, 2009, 3, 23-30.	0.8	2
50	CRP and the risk of atherosclerotic events. Seminars in Immunopathology, 2009, 31, 79-94.	2.8	103
51	Periodontitis and risk for atherosclerosis: an update on intervention trials. Journal of Clinical Periodontology, 2009, 36, 15-19.	2.3	164
52	Is androgenetic alopecia a risk for atherosclerosis?. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 673-677.	1.3	40
53	BDNF Val66Met polymorphism is associated with unstable angina. Clinica Chimica Acta, 2009, 400, 3-7.	0.5	33
54	The relationships among heart rate variability, inflammatory markers and depression in coronary heart disease patients. Brain, Behavior, and Immunity, 2009, 23, 1140-1147.	2.0	99
55	Risk Stratification of Patients With Severe Heart Failure Awaiting Heart Transplantationâ€"Prospective National Registry POLKARD HF. Transplantation Proceedings, 2009, 41, 3161-3165.	0.3	4

#	Article	IF	Citations
56	C-reactive protein predicts long-term mortality independently of low-density lipoprotein cholesterol in patients undergoing percutaneous coronary intervention. American Heart Journal, 2009, 158, 277-283.	1.2	31
58	Prediction rule for cardiovascular events and mortality in peripheral arterial disease patients: Data from the prospective Second Manifestations of ARTerial disease (SMART) cohort study. Journal of Vascular Surgery, 2009, 50, 1369-1376.	0.6	35
59	Low-grade inflammation in individuals with the hypertriglyceridemic waist phenotype: Another feature of the atherogenic dysmetabolism. Metabolism: Clinical and Experimental, 2009, 58, 661-667.	1.5	23
60	Use of High-Sensitivity C-Reactive Protein for Risk Assessment. , 2009, , 158-166.		0
61	Prognostic value of plasma high-sensitivity C-reactive protein levels in Japanese patients with stable coronary artery disease: The Japan NCVC-Collaborative Inflammation Cohort (JNIC) Study. Atherosclerosis, 2009, 207, 272-276.	0.4	51
62	Prognostic Value of High-Sensitivity C-Reactive Protein in Heart Failure: A Systematic Review. Journal of Cardiac Failure, 2009, 15, 256-266.	0.7	120
63	Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet, The, 2009, 373, 1175-1182.	6.3	886
64	Highly Sensitive C-Reactive Protein, Body Mass Index, and Serum Lipids in HIV-Infected Persons Receiving Antiretroviral Therapy: A Longitudinal Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, 480-487.	0.9	32
65	Elevated Serum C-Reactive Protein Levels Predict Cardiovascular Events in the Japanese Coronary Artery Disease (JCAD) Study. Circulation Journal, 2009, 73, 78-85.	0.7	27
66	Plasma C-Reactive Protein Levels Are Associated With Improved Outcome in ARDS. Chest, 2009, 136, 471-480.	0.4	75
67	Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients. Journal of Hypertension, 2010, 28, 2120-2126.	0.3	76
68	Higher Câ€Reactive Protein Predicts Worse Prognosis in Acute Heart Failure Only in Noninfected Patients. Clinical Cardiology, 2010, 33, 708-714.	0.7	26
69	Long-Term Prognostic Value of Preprocedural C-Reactive Protein After Drug-Eluting Stent Implantation. American Journal of Cardiology, 2010, 105, 826-832.	0.7	27
70	C-reactive protein in myocardial infarction binds to circulating microparticles but is not associated with complement activation. Clinical Immunology, 2010, 135, 490-495.	1.4	16
71	Can High-Sensitivity C-Reactive Protein and Plasma Homocysteine Levels Independently Predict the Prognosis of Patients with Functional Disability after First-Ever Ischemic Stroke?. European Neurology, 2010, 64, 304-310.	0.6	26
72	Association between Baseline Kidney Function and Change in CRP: An Analysis of the Cardiovascular Health Study. Nephron Clinical Practice, 2010, 115, c114-c121.	2.3	2
73	Impact of C-Reactive Protein and Pulse Pressure Evaluated at the Start of Peritoneal Dialysis on Cardiovascular Events in the Course of Treatment with Peritoneal Dialysis. Peritoneal Dialysis International, 2010, 30, 300-310.	1.1	8
74	The associations of cholesterol metabolism and plasma plant sterols with all-cause and cardiovascular mortality. Journal of Lipid Research, 2010, 51, 2384-2393.	2.0	87

#	Article	IF	Citations
75	Use of Biomarkers in Evaluation of Patients with Heart Failure. Contributions To Nephrology, 2010, 164, 88-117.	1.1	2
76	Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation. Journal of Clinical Lipidology, 2010, 4, 156-164.	0.6	158
77	Effect of atorvastatin on circulating hsCRP concentrations: A sub-study of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. International Journal of Cardiology, 2010, 142, 257-264.	0.8	14
78	Polymorphisms in the CRP gene moderate an association between depressive symptoms and circulating levels of C-reactive protein. Brain, Behavior, and Immunity, 2010, 24, 160-167.	2.0	53
79	Cardiac glycosides potently inhibit C-reactive protein synthesis in human hepatocytes. Biochemical and Biophysical Research Communications, 2010, 394, 233-239.	1.0	16
80	Does Vitamin D Modulate Asymmetric Dimethylarginine and C-Reactive Protein Concentrations?. American Journal of Medicine, 2010, 123, 335-341.	0.6	108
81	Gamma-glutamyltransferase and prognosis in patients with stable coronary heart disease followed over 8 years. Atherosclerosis, 2010, 210, 649-655.	0.4	23
82	Mild depression versus C-reactive protein as a predictor of cardiovascular death: a three year follow-up of patients with stable coronary artery disease. Current Medical Research and Opinion, 2011, 27, 1407-1413.	0.9	12
83	Comparison of Effects of Morning Versus Evening Administration of Ezetimibe/Simvastatin on Serum Cholesterol in Patients with Primary Hypercholesterolemia. Annals of Pharmacotherapy, 2011, 45, 841-849.	0.9	20
84	Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. Journal of Clinical Lipidology, 2011, 5, 338-367.	0.6	235
85	The Use of Biomarkers in the Evaluation of Heart Failure. , 2011, , 545-559.		1
86	A systematic review of the effectiveness of oral health promotion activities among patients with cardiovascular disease. International Journal of Cardiology, 2011, 151, 261-267.	0.8	34
87	A pattern of disperse plaque microcalcifications identifies a subset of plaques with high inflammatory burden in patients with acute myocardial infarction. Atherosclerosis, 2011, 218, 83-89.	0.4	12
88	Combined use of high-sensitivity C-reactive protein and apolipoprotein B/apolipoprotein A-1 ratio prior to elective coronary angiography and oral glucose tolerance tests. Clinical Biochemistry, 2011, 44, 1284-1291.	0.8	4
89	Comparison of C-reactive Protein Levels in Patients with Lung Cancer and Chronic Obstructive Pulmonary Disease. Medicina (Lithuania), 2011, 47, 421.	0.8	7
90	Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients with Stable Coronary Disease. Circulation, 2011, , 1.	1.6	0
92	Evaluation of cardiovascular biomarkers In HIV-infected patients switching to abacavir or tenofovir based therapy. BMC Infectious Diseases, 2011, 11, 267.	1.3	24
93	Dental Infection and Vascular Disease. Seminars in Thrombosis and Hemostasis, 2011, 37, 181-192.	1.5	46

#	Article	IF	Citations
94	High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial. Scandinavian Journal of Clinical and Laboratory Investigation, 2011, 71, 52-62.	0.6	30
95	C-Reactive Protein and High-Sensitivity C-Reactive Protein: An Update for Clinicians. Postgraduate Medicine, 2011, 123, 114-119.	0.9	133
96	High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial. Heart, 2011, 97, 626-631.	1.2	13
97	Trans-fatty acids in New Zealand patients with coronary artery disease. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 615-620.	3.1	13
98	Physical Activity and Cardiovascular Mortality Risk. Medicine and Science in Sports and Exercise, 2012, 44, 84-88.	0.2	48
99	Circulating Adipocyte Fatty Acid-Binding Protein Levels and Cardiovascular Morbidity and Mortality in Patients With Coronary Heart Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2327-2335.	1.1	103
100	Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients With Stable Coronary Disease. Circulation, 2012, 125, 233-240.	1.6	125
101	Haplotypes in theCRPGene Associated with Increased BMI and Levels of CRP in Subjects with Type 2 Diabetes or Obesity from Southwestern Mexico. Experimental Diabetes Research, 2012, 2012, 1-7.	3.8	19
102	MRI Measured Epicardial Adipose Tissue Thickness at the Right AV Groove Differentiates Inflammatory Status in Obese Men With Metabolic Syndrome. Obesity, 2012, 20, 525-532.	1.5	33
103	Predictive value of first fasting plasma glucose compared with admission plasma glucose for undiagnosed diabetes in a stable cardiology population. Clinical Biochemistry, 2012, 45, 1057-1063.	0.8	1
104	High-sensitivity C-reactive protein as a biomarker of risk in coronary artery disease. Revista Portuguesa De Cardiologia (English Edition), 2012, 31, 733-745.	0.2	41
105	Positive Psychological Attributes and Cardiac Outcomes: Associations, Mechanisms, and Interventions. Psychosomatics, 2012, 53, 303-318.	2.5	128
106	Detection of High-Risk Atherosclerotic Plaque. JACC: Cardiovascular Imaging, 2012, 5, 941-955.	2.3	198
109	Common variants in the CRP gene are associated with serum C-reactive protein levels and body mass index in healthy individuals in Mexico. Genetics and Molecular Research, 2012, 11, 2258-2267.	0.3	18
110	Hypertension. Global Advances in Health and Medicine, 2012, 1, 26-31.	0.7	2
111	High Sensitivity C-Reactive Protein Predicts Nonresponders and Cardiac Deaths in Severe Heart Failure Patients After CRT Implantation. International Heart Journal, 2012, 53, 306-312.	0.5	27
112	STAR VaS - Short Term Atorvastatin Regime for Vasculopathic Subjects: a randomized placebo-controlled trial evaluating perioperative atorvastatin therapy in noncardiac surgery. Canadian Journal of Anaesthesia, 2012, 59, 527-537.	0.7	15
113	C-reactive protein (CRP) is a predictor of high medical-care expenditures in a community-based elderly population aged 70 years and over: The Tsurugaya project. Archives of Gerontology and Geriatrics, 2012, 54, e392-e397.	1.4	6

#	Article	IF	Citations
114	Racial/ethnic and gender differences in the association between self-reported experiences of racial/ethnic discrimination and inflammation in the CARDIA cohort of 4 US communities. Social Science and Medicine, 2012, 75, 922-931.	1.8	88
115	Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: A prognostic study within the CLARICOR trial. Immunobiology, 2013, 218, 945-951.	0.8	29
116	The role of 14,15-dihydroxyeicosatrienoic acid levels in inflammation and its relationship to lipoproteins. Lipids in Health and Disease, 2013, 12, 151.	1.2	38
117	Hypertension in Pregnancy Is a Risk Factor for Microalbuminuria Later in Life. Journal of Clinical Hypertension, 2013, 15, 617-623.	1.0	37
118	Survivors of ventricular fibrillation have persistent cardiovascular risk factors late in follow-up. European Journal of Preventive Cardiology, 2013, 20, 161-167.	0.8	1
119	Administration of a Loading Dose of Atorvastatin Before Percutaneous Coronary Intervention Prevents Inflammation and Reduces Myocardial Injury in STEMI Patients: A Randomized Clinical Study. Clinical Therapeutics, 2013, 35, 261-272.	1.1	26
120	Severe Obesity in Children and Adolescents: Identification, Associated Health Risks, and Treatment Approaches. Circulation, 2013, 128, 1689-1712.	1.6	819
121	Inflammatory markers in heart failure. Journal of Cardiovascular Medicine, 2013, 14, 342-350.	0.6	4
122	The Impact of Ischemic Time on the Predictive Value of High-Sensitivity C-Reactive Protein in ST-Segment Elevation Myocardial Infarction Patients Treated by Primary Percutaneous Coronary Intervention. Korean Circulation Journal, 2013, 43, 664.	0.7	8
123	Ethanol Inhibits Activation of NLRP3 and AIM2 Inflammasomes in Human Macrophagesâ€“A Novel Anti-Inflammatory Action of Alcohol. PLoS ONE, 2013, 8, e78537.	1.1	47
124	Pentraxins: Structure, Function, and Role in Inflammation. ISRN Inflammation, 2013, 2013, 1-22.	4.9	193
125	Do Insulin Resistance Conditions Further Impair the Lipid and Inflammatory Profile in End-Stage Renal Disease Patients on Hemodialysis?. Metabolic Syndrome and Related Disorders, 2014, 12, 220-226.	0.5	3
126	Circulating acute phase proteins in relation to extent and composition of coronary atherosclerosis and cardiovascular outcome: Results from the ATHEROREMO-IVUS study. International Journal of Cardiology, 2014, 177, 847-853.	0.8	16
127	Circulating Osteoglycin and NGAL/MMP9 Complex Concentrations Predict 1-Year Major Adverse Cardiovascular Events After Coronary Angiography. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1078-1084.	1.1	53
128	Periodontal Disease, Renal Dysfunction and Heightened Leukocytosis. Nephron Clinical Practice, 2014, 128, 107-114.	2.3	15
129	Fibroblast Growth Factor-23, Cardiovascular Prognosis, and Benefit of Angiotensin-Converting Enzyme Inhibition in Stable Ischemic Heart Disease. Journal of the American College of Cardiology, 2014, 63, 2421-2428.	1.2	84
130	The association between circulating high-sensitivity C-reactive protein concentration and pathologic measures of colonic inflammation. Cancer Causes and Control, 2014, 25, 409-418.	0.8	10
131	Risk assessment of post-infarction heart failure. Systematic review on the role of emerging biomarkers. Critical Reviews in Clinical Laboratory Sciences, 2014, 51, 13-29.	2.7	39

#	Article	IF	Citations
132	Relation of C-Reactive Protein to Coronary Plaque Characteristics on Grayscale, Radiofrequency Intravascular Ultrasound, and Cardiovascular Outcome in Patients With Acute Coronary Syndrome or Stable Angina Pectoris (from the ATHEROREMO-IVUS Study). American Journal of Cardiology, 2014, 114, 1497-1503.	0.7	44
133	Potential Vascular Mechanisms of Ramipril Induced Increases in Walking Ability in Patients With Intermittent Claudication. Circulation Research, 2014, 114, 1144-1155.	2.0	8
134	Cardiac biomarkers in heart failure. Clinical Biochemistry, 2014, 47, 327-337.	0.8	48
135	Periodic limb movements during sleep and their effect on the cardiovascular system: is there a final answer?. Sleep Medicine, 2014, 15, 379-384.	0.8	31
136	Differences and Interactions between Risk Factors for Coronary Spasm and Atherosclerosis -Smoking, Aging, Inflammation, and Blood Pressure-. Internal Medicine, 2014, 53, 2663-2670.	0.3	24
137	Psychological Profile, Salivary Cortisol, C-Reactive Protein, and Perceived Health of Grandmothers With Childrearing Responsibility. Journal of Family Issues, 2015, 36, 1904-1927.	1.0	12
138	Increased Inflammatory Activity in Nonobese Patients with Coronary Artery Disease and Obstructive Sleep Apnea. Sleep, 2015, 38, 463-471.	0.6	36
139	The influence of low-grade inflammation on platelets in patients with stable coronary artery disease. Thrombosis and Haemostasis, 2015, 114, 519-529.	1.8	28
140	Chronic consumption of a low-fat diet improves cardiometabolic risk factors according to theCLOCKgene in patients with coronary heart disease. Molecular Nutrition and Food Research, 2015, 59, 2556-2564.	1.5	27
141	Association of Lipid Abnormalities with High-Sensitivity C - reactive Protein in Patients Treated with Atorvastatin. Journal of Diabetes & Metabolism, 2015, 06, .	0.2	0
142	Risk Factors of Coronary Artery Disease in Secondary Preventionâ€"Results from the AtheroGeneâ€"Study. PLoS ONE, 2015, 10, e0131434.	1.1	26
143	Body Mass Index, High-Sensitivity C-Reactive Protein and Mortality in Chinese with Coronary Artery Disease. PLoS ONE, 2015, 10, e0135713.	1.1	13
144	Predictive value of C-reactive protein in critically ill patients who develop acute lung injury. The Egyptian Journal of Chest Diseases and Tuberculosis, 2015, 64, 225-236.	0.1	3
145	Role of Pre-procedural C-reactive Protein Level in the Prediction of Major Adverse Cardiac Events in Patients Undergoing Percutaneous Coronary Intervention: a Meta-analysisof Longitudinal Studies. Inflammation, 2015, 38, 159-169.	1.7	19
146	Neonates with reduced neonatal lung function have systemic low-grade inflammation. Journal of Allergy and Clinical Immunology, 2015, 135, 1450-1456.e1.	1.5	33
147	Lipid Management. , 2015, , .		1
148	Cardiovascular Biomarker Assessment Across Glycemic Status. , 2015, , 245-268.		1
149	Traditional Risk Factors Versus Biomarkers for Prediction of Secondary Events in Patients With Stable Coronary Heart Disease: From the Heart and Soul Study. Journal of the American Heart Association, 2015, 4, .	1.6	41

#	Article	IF	Citations
150	Longitudinal Assessment of Inflammation in Recipients of Continuous-Flow Left Ventricular Assist Devices. Canadian Journal of Cardiology, 2015, 31, 348-356.	0.8	34
151	High-Sensitivity C-Reactive Protein and Statin Initiation. Angiology, 2015, 66, 503-507.	0.8	1
152	Coronary severity score and C-reactive protein predict major adverse cardiovascular events in patients with stable coronary artery disease (from the Taichung CAD study). Clinica Chimica Acta, 2015, 445, 93-100.	0.5	29
153	Metabolic fate of endogenous molecular damage: Urinary glutathione conjugates of DNA-derived base propenals as markers of inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4845-53.	3.3	11
154	Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT. Circulation, 2015, 132, 1224-1233.	1.6	267
155	Coronary Plaque Characteristics Assessed by 256-Slice Coronary CT Angiography and Association with High-Sensitivity C-Reactive Protein in Symptomatic Patients with Type 2 Diabetes. Journal of Diabetes Research, 2016, 2016, 1-6.	1.0	5
156	Plasma Lipoprotein-Associated Phospholipase A2 Level Is an Independent Predictor of High Thrombus Burden in Patients With Acute ST-segment Elevation Myocardial Infarction. International Heart Journal, 2016, 57, 689-696.	0.5	10
157	High-sensitivity C-reactive protein and mean platelet volume as predictive values after percutaneous coronary intervention for long-term clinical outcomes. Blood Coagulation and Fibrinolysis, 2016, 27, 70-76.	0.5	19
158	Prognostic Value of Epicardial Fat Thickness as a Biomarker of Increased Inflammatory. Status in Patients with Type 2 Diabetes Mellitus and Acute Myocardial Infarction. Journal of Cardiovascular Emergencies, 2016, 2, 11-18.	0.1	9
159	Prognostic Importance of Câ€Reactive Protein in High Cardiovascular Risk Patients With Type 2 Diabetes Mellitus: The Rio de Janeiro Type 2 Diabetes Cohort Study. Journal of the American Heart Association, 2016, 5, .	1.6	22
160	C-reactive protein level on admission and time to and cause of death in patients hospitalized for acute heart failure. European Heart Journal Quality of Care & Clinical Outcomes, 2016, 3, qcw054.	1.8	17
161	Clinical relevance of high sensitivity C-reactive protein in cardiology. Medicina (Lithuania), 2016, 52, 1-10.	0.8	57
162	The correlation between highly sensitive C-reactive protein levels and erectile function among men with late-onset hypogonadism. Aging Male, 2016, 19, 239-243.	0.9	18
163	Weight loss is superior to exercise in improving the atherogenic lipid profile in a sedentary, overweight population with stable coronary artery disease: A randomized trial. Atherosclerosis, 2016, 246, 221-228.	0.4	28
164	Prognostic Value of C-Reactive Protein in Resistant Hypertension. American Journal of Hypertension, 2016, 29, 992-1000.	1.0	18
165	Effects of exercise on c-reactive protein in healthy patients and in patients with heart disease: A meta-analysis. Heart and Lung: Journal of Acute and Critical Care, 2016, 45, 273-282.	0.8	43
166	Lifestyle associated diseases and risk of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. The Egyptian Journal of Chest Diseases and Tuberculosis, 2016, 65, 127-133.	0.1	4
167	Brain-derived neurotrophic factor rs6265 (Val66Met) polymorphism is associated with disease severity and incidence of cardiovascular events in a patient cohort. American Heart Journal, 2017, 190, 40-45.	1.2	25

#	Article	IF	Citations
168	The Clinical Importance of Periodic Leg Movements in Sleep. Current Treatment Options in Neurology, 2017, 19, 10.	0.7	25
169	Pathway-Specific Aggregate Biomarker Risk Score Is Associated With Burden of Coronary Artery Disease and Predicts Near-Term Risk of Myocardial Infarction and Death. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	21
170	State of the Art: Blood Biomarkers for Risk Stratification in Patients with Stable Ischemic Heart Disease. Clinical Chemistry, 2017, 63, 165-176.	1.5	35
171	Allergic sensitization at school age is a systemic lowâ€grade inflammatory disorder. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1073-1080.	2.7	15
172	Cumulative Exposure to Highâ€Sensitivity Câ€Reactive Protein Predicts the Risk of Cardiovascular Disease. Journal of the American Heart Association, 2017, 6, .	1.6	57
173	High-sensitivity C reactive protein as a predictor of inhospital mortality in patients with cardiovascular disease at an emergency department: a retrospective cohort study. BMJ Open, 2017, 7, e015112.	0.8	21
174	No further gain can be achieved by calculating Disease Activity Score in 28 joints with high-sensitivity assay of C-reactive protein because of high intraindividual variability of C-reactive protein. Medicine (United States), 2017, 96, e5781.	0.4	6
175	Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.4	62
176	Neutrophil gelatinase-associated lipocalin as a risk marker in cardiovascular disease. Clinical Chemistry and Laboratory Medicine, 2017, 56, 5-18.	1.4	45
177	An Aggregate Biomarker Risk Score Predicts High Risk of Nearâ€Term Myocardial Infarction and Death: Findings From BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes). Journal of the American Heart Association, 2017, 6, .	1.6	9
178	Effect of ezetimibe add-on therapy over 52Âweeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease, 2017, 16, 122.	1.2	16
179	Observational Prospective study to esTIMAte the rates of outcomes in patients undergoing PCI with drug-eluting stent implantation who take statins â€“follow-up (OPTIMA II). Current Medical Research and Opinion, 2017, 33, 253-259.	0.9	0
180	Prevalence and predictors of elevated highâ€sensitivity Câ€reactive protein in postâ€“myocardial infarction patients: Insights from the VIRGO and TRIUMPH registries. Clinical Cardiology, 2017, 40, 1205-1211.	0.7	7
181	Natriuretic Peptides as Biomarkers for Congestive States: The Cardiorenal Divergence. Disease Markers, 2017, 2017, 1-9.	0.6	19
182	Preprocedural High-Sensitivity C-Reactive Protein Predicts Long-Term Outcome of Percutaneous Coronary Intervention. Circulation Journal, 2017, 81, 90-95.	0.7	28
183	Independent and Combined Effects of Serum Albumin and C-Reactive Protein on Long-Term Outcomes of Patients Undergoing Percutaneous Coronary Intervention. Circulation Journal, 2017, 81, 1293-1300.	0.7	41
184	Relationship between Syntax Score and prognostic localization of coronary artery lesions with conventional risk factors, plasma profile markers, and carotid atherosclerosis (CAPP Study 2). International Journal of Cardiology, 2018, 257, 306-311.	0.8	11
185	Singleâ€Molecule Counting of Highâ€Sensitivity Troponin I in Patients Referred for Diagnostic Angiography: Results From the CASABLANCA (Catheter Sampled Blood Archive in Cardiovascular) Tj ETQq1 1 0.784314 rgBT /Overlock	13.4	10

#	Article	IF	Citations
186	Neonates colonized with pathogenic bacteria in the airways have a lowâ€grade systemic inflammation. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 2150-2159.	2.7	12
187	The prevalence and predictors of elevated C-reactive protein after a coronary heart disease event. European Journal of Preventive Cardiology, 2018, 25, 923-931.	0.8	31
188	Is there a C-reactive protein value beyond which one should consider infection as the cause of acute heart failure?. BMC Cardiovascular Disorders, 2018, 18, 40.	0.7	7
189	Inflammatory and Cholesterol Risk in the FOURIER Trial. Circulation, 2018, 138, 131-140.	1.6	194
190	The hidden risk: Incorporating inflammation and HIV serostatus into coronary artery disease screening. Journal of Nuclear Cardiology, 2018, 25, 884-886.	1.4	0
191	Biomarkers in stable coronary artery disease. American Heart Journal, 2018, 196, 82-96.	1.2	39
192	Immunosensor for electrodetection of the C-reactive protein in serum. Journal of Solid State Electrochemistry, 2018, 22, 1365-1372.	1.2	15
193	Prognostic value of urinary 11â€dehydroâ€thromboxane B₂ for mortality: A cohort study of stable coronary artery disease patients treated with aspirin. Catheterization and Cardiovascular Interventions, 2018, 92, 653-658.	0.7	6
194	Impact of anemia on longâ€term outcomes after percutaneous coronary intervention for chronic total occlusion. Catheterization and Cardiovascular Interventions, 2018, 91, 226-233.	0.7	6
195	Standard and Novel Biomarkers. , 2018, , 98-113.		1
196	OBSOLETE: Biomarkers in Ischemic Heart Disease. , 2018, , .		0
197	Facilitating Earlier Diagnosis of Cardiovascular Disease through Point-of-Care Biosensors: A Review. Critical Reviews in Biomedical Engineering, 2018, 46, 53-82.	0.5	9
198	Neutrophil gelatinase-associated lipocalin (NGAL) and cardiovascular events in patients with stable coronary artery disease. Scandinavian Journal of Clinical and Laboratory Investigation, 2018, 78, 470-476.	0.6	13
199	Systemic inflammation and eye diseases. The Beijing Eye Study. PLoS ONE, 2018, 13, e0204263.	1.1	11
200	Evidence-based nutritional and pharmacological interventions targeting chronic low-grade inflammation in middle-age and older adults: A systematic review and meta-analysis. Ageing Research Reviews, 2018, 46, 42-59.	5.0	111
201	Biomarkers in Ischemic Heart Disease. , 2018, , 303-314.		0
202	Lack of Association betweenHelicobacter pyloriInfection and Various Markers of Systemic Inflammation in Asymptomatic Adults. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2018, 72, 21.	0.2	16
203	High-sensitivity C-reactive protein elevation in patients with prior myocardial infarction in the United States. American Heart Journal, 2018, 204, 151-155.	1.2	10

#	Article	IF	Citations
204	The Emerging Role of Biomarkers in the Diagnosis of Gestational Diabetes Mellitus. Journal of Clinical Medicine, 2018, 7, 120.	1.0	47
205	Dynamic Macrophages: Understanding Mechanisms of Activation as Guide to Therapy for Atherosclerotic Vascular Disease. Frontiers in Cardiovascular Medicine, 2018, 5, 97.	1.1	21
206	Serum-soluble (pro)renin receptor concentration as a biomarker for organ damage in primary aldosteronism. Hypertension Research, 2019, 42, 1951-1960.	1.5	4
207	Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial. Atherosclerosis, 2019, 288, 60-66.	0.4	43
208	The Effectiveness of Mediterranean Diet in Nonalcoholic Fatty Liver Disease Clinical Course: An Intervention Study. Journal of Medicinal Food, 2019, 22, 729-740.	0.8	16
209	Association of inflammatory biomarkers with lung cancer in North Indian population. African Health Sciences, 2019, 19, 2147.	0.3	9
210	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis, 2019, 290, 140-205.	0.4	1,753
211	High-sensitivity C-reactive protein and hypertension: combined effects on coronary severity and cardiovascular outcomes. Hypertension Research, 2019, 42, 1783-1793.	1.5	14
212	hsCRP Level and the Risk of Death or Recurrent Cardiovascular Events in Patients With Myocardial Infarction: a Healthcareâ€Based Study. Journal of the American Heart Association, 2019, 8, e012638.	1.6	79
213	Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure. Scientific Reports, 2019, 9, 8552.	1.6	31
214	Inflammation during acute coronary syndromes â€" Risk of cardiovascular events and bleeding. International Journal of Cardiology, 2019, 287, 13-18.	0.8	22
215	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020, 41, 111-188.	1.0	4,871
216	Serum proâ€inflammatory factors as predictors of persistent diabetic macular oedema with limited anatomic response to antiâ€VEGF : association with intravitreal injection treatment profiles in realâ€world setting. Acta Ophthalmologica, 2020, 98, e421-e427.	0.6	3
217	Reduction in hsCRP levels is associated with decreased incidence of cardiovascular events in Japanese hypertensive women but not in men. Scientific Reports, 2020, 10, 17040.	1.6	7
218	Mediation analysis for the relationship between dyslipidemia and coronary artery disease via hypersensitive C-reactive protein in a case-control study. Coronary Artery Disease, 2020, 31, 613-619.	0.3	12
219	Impact of Cinnamon Supplementation on cardiometabolic Biomarkers of Inflammation and Oxidative Stress: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Complementary Therapies in Medicine, 2020, 53, 102517.	1.3	23
220	Identification of plaque ruptures using a novel discriminative model comprising biomarkers in patients with acute coronary syndrome. Scientific Reports, 2020, 10, 20228.	1.6	10
221	Oxidized Low-Density Lipoprotein Associates with Ventricular Stress in Young Adults and Triggers Intracellular Ca2+ Alterations in Adult Ventricular Cardiomyocytes. Antioxidants, 2020, 9, 1213.	2.2	7

#	Article	IF	Citations
222	Effects of intermittent fasting diets on plasma concentrations of inflammatory biomarkers: A systematic review and meta-analysis of randomized controlled trials. Nutrition, 2020, 79-80, 110974.	1.1	48
223	Lifetime duration of lactation and chronic inflammation among middle-aged women with a history of gestational diabetes. BMJ Open Diabetes Research and Care, 2020, 8, e001229.	1.2	0
224	Metabolic syndrome and risk of pancreatic cancer: A populationâ€based prospective cohort study. International Journal of Cancer, 2020, 147, 3384-3393.	2.3	30
225	Effects of green coffee bean extract on C-reactive protein levels: A systematic review and meta-analysis of randomized controlled trials. Complementary Therapies in Medicine, 2020, 52, 102498.	1.3	7
226	Diagnostic and prognostic value of serum C-reactive protein in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart Failure Reviews, 2021, 26, 1141-1150.	1.7	37
227	The effects of pomegranate supplementation on biomarkers of inflammation and endothelial dysfunction: A meta-analysis and systematic review. Complementary Therapies in Medicine, 2020, 49, 102358.	1.3	42
228	Residual Inflammation Indicated by High-Sensitivity C-Reactive Protein Predicts Worse Long-Term Clinical Outcomes in Japanese Patients after Percutaneous Coronary Intervention. Journal of Clinical Medicine, 2020, 9, 1033.	1.0	4
229	IL-8 and CRP moderate the effects of preoperative psychological interventions on postoperative long-term outcomes 6Âmonths after CABG surgery â€“ The randomized controlled PSY-HEART trial. Brain, Behavior, and Immunity, 2021, 91, 202-211.	2.0	6
230	Combating Inflammation in Cardiovascular Disease. Heart Lung and Circulation, 2021, 30, 197-206.	0.2	39
231	Modifiable lifestyle risk factors and C-reactive protein in patients with coronary artery disease: Implications for an anti-inflammatory treatment target population. European Journal of Preventive Cardiology, 2021, 28, 152-158.	0.8	34
232	Relationship between plasma high-sensitivity C-reactive protein and traditional cardiovascular risk factors among active-duty military personnel in the Republic of Serbia. Vojnosanitetski Pregled, 2022, 79, 714-723.	0.1	2
234	Role of Serum High-Sensitivity C-Reactive Protein Level as Risk Factor in the Prediction of Coronary Artery Disease in Hyperglycemic Subjects. , 2021, , 123-134.		0
235	Circulating PGLYRP1 Levels as a Potential Biomarker for Coronary Artery Disease and Heart Failure. Journal of Cardiovascular Pharmacology, 2021, 77, 578-585.	0.8	11
236	High Sensitivity C-reactive Protein (hsCRP) and its Implications in Cardiovascular Outcomes. Current Pharmaceutical Design, 2021, 27, 263-275.	0.9	27
237	Biomarkers of Inflammation and Risk of Hospitalization for Heart Failure in Patients With Atrial Fibrillation. Journal of the American Heart Association, 2021, 10, e019168.	1.6	12
238	Weight loss and its influence on high-density lipoprotein cholesterol (HDL-C) concentrations: A noble clinical hesitation. Clinical Nutrition ESPEN, 2021, 42, 90-92.	0.5	32
239	A Review of Inflammatory Bowel Disease: A Model of Microbial, Immune and Neuropsychological Integration. Public Health Reviews, 2021, 42, 1603990.	1.3	43
240	The effect of metabolic syndrome on head and neck cancer incidence risk: a population-based prospective cohort study. Cancer & Metabolism, 2021, 9, 25.	2.4	8

#	Article	IF	Citations
241	Central obesity is a contributor to systemic inflammation and monocyte activation in virally suppressed adults with chronic HIV in Kenya. Aids, 2021, 35, 1723-1731.	1.0	3
242	Circulating Biomarkers Reflecting Destabilization Mechanisms of Coronary Artery Plaques: Are We Looking for the Impossible?. Biomolecules, 2021, 11, 881.	1.8	16
243	Can biomarkers be used to improve diagnosis and prediction of metabolic syndrome in childhood cancer survivors? A systematic review. Obesity Reviews, 2021, 22, e13312.	3.1	11
244	Atherosclerotic Burden and Mortality. , 2010, , 899-918.		5
245	C-reactive protein in acute coronary syndrome: association with 3-year outcomes. Brazilian Journal of Medical and Biological Research, 2009, 42, 1236-1241.	0.7	4
246	The Role of C-Reactive Protein in Atherosclerotic Cardiovascular Disease: An Overview. Current Vascular Pharmacology, 2008, 6, 258-270.	0.8	49
247	Update on the Pathophysiological Role of Intracellular Signaling Pathways in Atherosclerotic Plaques and Ischemic Myocardium. Current Signal Transduction Therapy, 2012, 7, 104-110.	0.3	4
248	Expanded Network of Inflammatory Markers of Atherogenesis: Where Are We Now?. Open Cardiovascular Medicine Journal, 2010, 4, 38-44.	0.6	6
249	Expanded Network of Inflammatory Markers of Atherogenesis: Where Are We Now?~!2009-11-07~!2009-12-10~!2010-02-22~!. Open Cardiovascular Medicine Journal, 2010, 4, 38-44.	0.6	11
250	SHORT-TERM EFFECTS OF TESTOSTERONE REPLACEMENT THERAPY ON RISK PREDICTORS FOR ARTERIOSCLEROSIS AMONG MEN WITH LATE-ONSET HYPOGONADISM: A CASEâ€“CONTROL STUDY. Journal of Men's Health, 2020, 16, 65.	0.1	3
251	Major depressive disorder is a risk factor for low bone mass, central obesity, and other medical conditions. Dialogues in Clinical Neuroscience, 2011, 13, 73-87.	1.8	41
252	Metabolic syndrome and its components are strongly associated with an inflammatory state and insulin resistance in the pediatric population. Nutricion Hospitalaria, 2015, 31, 1513-8.	0.2	7
253	The effectiveness and cost-effectiveness of biomarkers for the prioritisation of patients awaiting coronary revascularisation: a systematic review and decision model. Health Technology Assessment, 2010, 14, 1-151, iii-iv.	1.3	21
254	Randomised Assessment of Treatment using Panel Assay of Cardiac markers â€“ Contemporary Biomarker Evaluation (RATPAC CBE). Health Technology Assessment, 2013, 17, v-vi, 1-122.	1.3	36
255	Using nationwide â€˜big dataâ€™ from linked electronic health records to help improve outcomes in cardiovascular diseases: 33 studies using methods from epidemiology, informatics, economics and social science in the ClinicAl disease research using LInked Bespoke studies and Electronic health Records (CALIBER) programme. Programme Grants for Applied Research, 2017, 5, 1-330.	0.4	17
256	CRP Induces NETosis in Heart Failure Patients with or without Diabetes. ImmunoHorizons, 2019, 3, 378-388.	0.8	28
257	Marcadores de inflamaciÃ³n endotelial subclÃnica en una familia con hiperaldosteronismo familiar tipo I por mutaciÃ³n de novo. Revista Medica De Chile, 2008, 136, .	0.1	5
258	Independent Prognostic Value of High-sensitivity C-reactive Protein in Patients with Coronary Artery Ectasia. Chinese Medical Journal, 2016, 129, 2582-2588.	0.9	8

#	Article	IF	Citations
259	Serum levels of high-sensitivity C-reactive protein in acute ischemic stroke and its subtypes: a prospective case-control study. Asia Pacific Journal of Clinical Trials Nervous System Diseases, 2018, 3, 128.	0.3	7
260	High-sensitivity C-reactive protein predicts 10-year cardiovascular outcome after percutaneous coronary intervention. EuroIntervention, 2016, 12, 345-351.	1.4	24
261	Autoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunity. World Journal of Cardiology, 2014, 6, 314.	0.5	24
262	Polymorphisms of tumor necrosis factor-alpha and interleukin-6 gene and C-reactive protein profiles in patients with idiopathic dilated cardiomyopathy. Annals of Saudi Medicine, 2014, 34, 407-414.	0.5	10
264	Evaluation of the relationship between the levels of high-sensitivity C-reactive protein and saphenous vein graft disease. Turkish Journal of Thoracic and Cardiovascular Surgery, 2013, 21, 268-275.	0.2	3
265	The association between serum high-sensitivity cardiac troponin T and acute myocardial infarction in patients with suspected chronic coronary syndrome is modified by body mass index. International Journal of Cardiology Cardiovascular Risk and Prevention, 2021, 11, 200109.	0.4	2
266	The Plasma Adiponectin Levels in Patients with Newly Diagnosed Type 2 Diabetes. The Journal of Korean Diabetes Association, 2007, 31, 507.	0.1	0
267	Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease. Yearbook of Pathology and Laboratory Medicine, 2008, 2008, 337-338.	0.0	0
268	Mechanistic and Methodological Considerations for the Imaging of Mental Stress Ischemia. , 2010, , 491-505.		0
269	The growth hormone - insulinlike growth factor-1 axis at different phases of chronic heart failure development. Arterial Hypertension (Russian Federation), 2010, 16, 299-304.	0.1	2
270	Plasma asymmetric dimethylarginine and nitric oxide levels on early prognosis in patients with myocardial infarction. Ä°stanbul Medical Journal, 2011, 12, 153-158.	0.1	0
271	Risk Markers for Atherothrombotic Disease. , 2012, , 914-934.		6
272	High-Sensitivity C-Reactive Protein: To Measure or not to Measure?~!2009-10-29~!2009-12-22~!2010-04-08~!. The Open Clinical Chemistry Journal, 2012, 3, 10-18.	0.7	0
273	C-Reactive Protein is not an Independent Risk Factor for Ventricular Thrombus. Journal of Turgut Ozal Medical Center, 2012, 19, 66-70.	0.0	0
274	High Sensitivity C-reactive Protein and Cardiovascular Risk Prediction. Current Pharmaceutical Analysis, 2014, 11, 60-65.	0.3	3
275	Lipid and Inflammation in Atherosclerosis. , 2015, , 37-63.		0
276	Adipocyte fatty acid binding protein levels in patients with coronary artery disease and its relationship to alternative biomarkers. Kardiologia Polska, 2015, 73, 94-100.	0.3	1
277	ROLE OF METABOLIC SYNDROME AND PRO-INFLAMMATORY STATUS AS POTENTIAL CARDIOVASCULAR RISK FACTORS IN TWENTY TO FIFTY YEARS AGE GROUP IN AN URBAN AREA. Journal of Evolution of Medical and Dental Sciences, 2016, 5, 5154-5160.	0.1	0

#	Article	IF	Citations
278	Association between Biomarkers of Oxidative Stress and Inflammation with Cardiac Necrosis and Heart Failure in Non-ST Segment Elevation Myocardial Infarction Patients and Various Degrees of Kidney Function. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-12.	1.9	12
279	Homocysteine and C-reactive protein levels in women with polycystic ovary syndrome. Gynecology and Minimally Invasive Therapy, 2021, 10, 210.	0.2	3
280	The Plasma Adiponectin Levels in Patients with Newly Diagnosed Type 2 Diabetes. The Journal of Korean Diabetes Association, 2007, 31, 507.	0.1	0
282	Variation in high-sensitivity C-reactive protein levels over 24 hours in patients with stable coronary artery disease. Texas Heart Institute Journal, 2010, 37, 42-8.	0.1	21
283	High sensitivity C-reactive protein levels in Acute Ischemic Stroke and subtypes: A study from a tertiary care center. Iranian Journal of Neurology, 2013, 12, 92-7.	0.5	17
284	Value of C-reactive Protein/Albumin Ratio for Predicting Ischemia in Myocardial Perfusion Scintigraphy. Molecular Imaging and Radionuclide Therapy, 2020, 29, 112-117.	0.3	0
285	Combined impact of residual inflammatory risk and chronic kidney disease on long-term clinical outcomes in patients undergoing percutaneous coronary intervention. Journal of Cardiology, 2021, , .	0.8	1
286	Value of C-reactive Protein/Albumin Ratio for Predicting Ischemia in Myocardial Perfusion Scintigraphy. Molecular Imaging and Radionuclide Therapy, 2020, 29, 112-117.	0.3	5
287	Does tibolone treatment have favorable effects on obesity, blood pressure, and inflammation? A meta-analysis of randomized controlled trials. Steroids, 2022, 178, 108966.	0.8	3
288	The effects of raloxifene on endothelial function and Inflammation in Postmenopausal women: A Meta-analysis of randomized controlled trials. Experimental Gerontology, 2022, 159, 111682.	1.2	4
289	Blood-based and Imaging Biomarkers of Atherosclerosis. Cardiology in Review, 2022, Publish Ahead of Print, .	0.6	1
290	Biochemical clusters predict mortality and reported inability to work 10Ââ€‹years later. Brain, Behavior, & Immunity - Health, 2022, 21, 100432.	1.3	1
291	Residual Inflammatory Risk and its Association With Events in East Asian Patients After Coronary Intervention. JACC Asia, 2022, 2, 323-337.	0.5	5
293	Higher frequency of cardiovascular autonomic neuropathy in youth with type 2 compared to type 1 diabetes: Role of cardiometabolic risk factors. Pediatric Diabetes, 2022, 23, 1073-1079.	1.2	3
294	Predictive value of baseline C-reactive protein level in patients with stable coronary artery disease: A meta-analysis. Medicine (United States), 2022, 101, e30285.	0.4	2
295	Comparison of High-Sensitivity C-Reactive Protein vs C-reactive Protein for Cardiovascular Risk Prediction in Chronic Cardiac Disease. journal of applied laboratory medicine, The, 2022, 7, 1259-1271.	0.6	4
296	Elevated C-Reactive Protein and Subsequent Patient-Reported Cognitive Problems in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study. Journal of Clinical Oncology, 2023, 41, 295-306.	0.8	10
297	The Association between High-Sensitivity C-Reactive Protein and Metabolic Syndrome in an Elderly Population Aged 50 and Older in a Community Receiving Primary Health Care in Taiwan. International Journal of Environmental Research and Public Health, 2022, 19, 13111.	1.2	6

#	Article	IF	Citations
298	The critical issue linking lipids and inflammation: Clinical utility of stopping oxidative stress. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	6
299	Plant-Based Diets and Lipid, Lipoprotein, and Inflammatory Biomarkers of Cardiovascular Disease: A Review of Observational and Interventional Studies. Nutrients, 2022, 14, 5371.	1.7	8
300	The Presence of Residual Vascular and Adipose Tissue Inflammation on 18F-FDG PET in Patients with Chronic Coronary Artery Disease. Nuclear Medicine and Molecular Imaging, 0, , .	0.6	1
301	Post-PCI Risk Assessment by Inflammation Activity According to Disease Acuity and Time from Procedure. Thrombosis and Haemostasis, 0, , .	1.8	1
302	Intracranial plaque characteristics on high-resolution MRI and high-sensitivity C-reactive protein levels: association and clinical relevance in acute cerebral infarction. Clinical Radiology, 2023, , .	0.5	0
303	Effect of testosterone undecanoate on sexual functions, glycaemic parameters, and cardiovascular risk factors in hpogonadal men with type 2 diabetes mellitus. Indian Journal of Endocrinology and Metabolism, 2022, 26, 565.	0.2	0
304	Bempedoic Acid for Lipid Management in the Indian Population: An Expert Opinion. Cureus, 2023, , .	0.2	1
305	Prognostic impact of white blood cell counts on clinical outcomes in patients with chronic renal insufficiency undergoing percutaneous coronary intervention. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	0